Journal of Clinical Oncology, Vol 16, 3628-3633, Copyright © 1998 by American Society of Clinical Oncology

ARTICLES

Ifosfamide-containing chemotherapy in Ewing's sarcoma: The Second United Kingdom Children's Cancer Study Group and the Medical Research Council Ewing's Tumor Study

A Craft, S Cotterill, A Malcolm, D Spooner, R Grimer, R Souhami, J Imeson and I Lewis
United Kingdom Children's Cancer Study Group and the Medical Research Council Bone Sarcoma Working Party. a.w.craft@ncl.ac.uk

PURPOSE: To investigate the possibility that the substitution of ifosfamide for cyclophosphamide therapy for Ewing's sarcoma will improve survival over that seen in the first United Kingdom Children's Cancer Study Group (UKCCSG) Ewing's tumor study (ET-1). PATIENTS AND METHODS: Between 1987 and 1993,243 patients (138 men or boys) were entered onto the study. The median age was 13.5 years (range, 1.5 to 27 years). The median follow-up was 58 months. Chemotherapy included four courses of vincristine 2 mg/m2; ifosfamide 9 g/m2; and doxorubicin 60 mg/m2 administered every 3 weeks. Treatment of the primary tumor was with surgery and/or radiotherapy followed by ifosfamide 6 g/m2; doxorubicin 60 mg/m2; and vincristine 2 mg/m2; with actinomycin D 1.5 mg/m2 substituted for doxorubicin after a total dose of 420 mg/m2. RESULTS: Two hundred one patients had no metastases. One hundred eighteen patients had tumors of the axial skeleton and 125 patients had limb primary tumors. The major toxicities were hematologic and infective, but there were no toxic deaths. The overall survival rate was 62% (95% confidence interval [CI], 56 to 69) and relapse-free survival (RFS) 56% (95% CI, 49 to 62). For those with no metastases at diagnosis, the RFS rate was 62% and for those with metastases, 23%. Multivariate analysis showed age and site to have a significant effect on RFS. Pelvic sites had the worst RFS rate of 41%; other axial sites, 55%; and extremity tumors, 73%. Age younger than 10 years had an RFS rate of 86% versus 55% for older patients. The local relapse rate for axial tumors was 20% and for limb primary tumors was 2.4%. CONCLUSION: The 5-year survival rate of 62% is improved compared with the 44% survival rate achieved in ET-1. This is probably caused by the use of higher doses of ifosfamide compared with relatively low doses of cyclophosphamide in ET-1.

This article has been cited by other articles:

				M. Paulussen, A. W. Craft, I. Lewis, A. Hackshaw, C. Douglas, J. Dunst, A. Schuck, W. Winkelmann, G. Kohler, C. Poremba, et al. Results of the EICESS-92 Study: Two Randomized Trials of Ewing's Sarcoma Treatment--Cyclophosphamide Compared With Ifosfamide in Standard-Risk Patients and Assessment of Benefit of Etoposide Added to Standard Treatment in High-Risk Patients J. Clin. Oncol., September 20, 2008; 26(27): 4385 - 4393. [Abstract] [Full Text] [PDF]

				O. Oberlin, A. Rey, A. S. Desfachelles, T. Philip, D. Plantaz, C. Schmitt, E. Plouvier, O. Lejars, H. Rubie, P. Terrier, et al. Impact of High-Dose Busulfan Plus Melphalan As Consolidation in Metastatic Ewing Tumors: A Study by the Societe Francaise des Cancers de l'Enfant J. Clin. Oncol., August 20, 2006; 24(24): 3997 - 4002. [Abstract] [Full Text] [PDF]

				M. Bernstein, H. Kovar, M. Paulussen, R. L. Randall, A. Schuck, L. A. Teot, and H. Juergensg Ewing's Sarcoma Family of Tumors: Current Management. Oncologist, May 1, 2006; 11(5): 503 - 519. [Abstract] [Full Text] [PDF]

				J.S. Pekala, S. Gururangan, J.M. Provenzale, and S. Mukundan Jr. Central Nervous System Extraosseous Ewing Sarcoma: Radiologic Manifestations of This Newly Defined Pathologic Entity AJNR Am. J. Neuroradiol., March 1, 2006; 27(3): 580 - 583. [Abstract] [Full Text] [PDF]

				M. Scurr and I. Judson How to Treat the Ewing's Family of Sarcomas in Adult Patients Oncologist, January 1, 2006; 11(1): 65 - 72. [Abstract] [Full Text] [PDF]

				G. Bacci, S. Ferrari, A. Longhi, D. Donati, M. De Paolis, C. Forni, M. Versari, E. Setola, A. Briccoli, and E. Barbieri Therapy and survival after recurrence of Ewing's tumors: the Rizzoli experience in 195 patients treated with adjuvant and neoadjuvant chemotherapy from 1979 to 1997 Ann. Onc., November 1, 2003; 14(11): 1654 - 1659. [Abstract] [Full Text] [PDF]

				E. A. Kolb, B. H. Kushner, R. Gorlick, C. Laverdiere, J. H. Healey, M. P. LaQuaglia, A. G. Huvos, J. Qin, H. T. Vu, L. Wexler, et al. Long-Term Event-Free Survival After Intensive Chemotherapy for Ewing's Family of Tumors in Children and Young Adults J. Clin. Oncol., September 15, 2003; 21(18): 3423 - 3430. [Abstract] [Full Text] [PDF]

				G. Saeter ESMO Minimum Clinical Recommendations for diagnosis, treatment and follow-up of Ewing's sarcoma of bone Ann. Onc., August 1, 2003; 14(8): 1167 - 1168. [Full Text] [PDF]

				S.J. Strauss, A. McTiernan, D. Driver, M. Hall-Craggs, A. Sandison, A.M. Cassoni, A. Kilby, M. Michelagnoli, J. Pringle, J. Cobb, et al. Single Center Experience of a New Intensive Induction Therapy for Ewing's Family of Tumors: Feasibility, Toxicity, and Stem Cell Mobilization Properties J. Clin. Oncol., August 1, 2003; 21(15): 2974 - 2981. [Abstract] [Full Text] [PDF]

				K. Scotlandi, M. C. Manara, R. Strammiello, L. Landuzzi, S. Benini, S. Perdichizzi, M. Serra, A. Astolfi, G. Nicoletti, P.-L. Lollini, et al. c-kit Receptor Expression in Ewing's Sarcoma: Lack of Prognostic Value but Therapeutic Targeting Opportunities in Appropriate Conditions J. Clin. Oncol., May 15, 2003; 21(10): 1952 - 1960. [Abstract] [Full Text] [PDF]

				H. E. Grier, M. D. Krailo, N. J. Tarbell, M. P. Link, C. J.H. Fryer, D. J. Pritchard, M. C. Gebhardt, P. S. Dickman, E. J. Perlman, P. A. Meyers, et al. Addition of Ifosfamide and Etoposide to Standard Chemotherapy for Ewing's Sarcoma and Primitive Neuroectodermal Tumor of Bone N. Engl. J. Med., February 20, 2003; 348(8): 694 - 701. [Abstract] [Full Text] [PDF]

				K. Scotlandi, S. Perdichizzi, M. C. Manara, M. Serra, S. Benini, V. Cerisano, R. Strammiello, M. Mercuri, G. Reverter-Branchat, G. Faircloth, et al. Effectiveness of Ecteinascidin-743 against Drug-sensitive and -resistant Bone Tumor Cells Clin. Cancer Res., December 1, 2002; 8(12): 3893 - 3903. [Abstract] [Full Text] [PDF]

				K. Kimura, S. Tatezaki, T. Ishii, T. Yonemoto, T. Shigehara, and T. Takenouchi Hemiarthroplasty of the Elbow with a Vascularized Fibular Graft after Excision of Ewing's Sarcoma of the Proximal Ulna: a Case Report Jpn. J. Clin. Oncol., October 1, 2002; 32(10): 430 - 434. [Abstract] [Full Text] [PDF]

				C. P. Gibbs Jr., K. Weber, and M. T. Scarborough Malignant Bone Tumors J. Bone Joint Surg. Am., November 1, 2001; 83(11): 1728 - 1745. [Full Text] [PDF]

				S. Benini, M. C. Manara, N. Baldini, V. Cerisano, Massimo Serra, M. Mercuri, P.-L. Lollini, P. Nanni, P. Picci, and K. Scotlandi Inhibition of Insulin-like Growth Factor I Receptor Increases the Antitumor Activity of Doxorubicin and Vincristine against Ewing's Sarcoma Cells Clin. Cancer Res., June 1, 2001; 7(6): 1790 - 1797. [Abstract] [Full Text] [PDF]

				B. H. Kushner and P. A. Meyers How Effective Is Dose-Intensive/Myeloablative Therapy Against Ewing's Sarcoma/Primitive Neuroectodermal Tumor Metastatic to Bone or Bone Marrow? The Memorial Sloan-Kettering Experience and a Literature Review J. Clin. Oncol., February 1, 2001; 19(3): 870 - 880. [Abstract] [Full Text] [PDF]

				B. E. C. Plaat, H. Hollema, W. M. Molenaar, G. H. T. Broers, J. Pijpe, M. F. Mastik, H. J. Hoekstra, E. van den Berg, R. J. Scheper, and W. T. A. van der Graaf Soft Tissue Leiomyosarcomas and Malignant Gastrointestinal Stromal Tumors: Differences in Clinical Outcome and Expression of Multidrug Resistance Proteins J. Clin. Oncol., September 18, 2000; 18(18): 3211 - 3220. [Abstract] [Full Text] [PDF]

				S.J. Cotterill, S. Ahrens, M. Paulussen, H.F. Jurgens, P.A. Voute, H. Gadner, and A.W. Craft Prognostic Factors in Ewing's Tumor of Bone: Analysis of 975 Patients From the European Intergroup Cooperative Ewing's Sarcoma Study Group J. Clin. Oncol., September 17, 2000; 18(17): 3108 - 3114. [Abstract] [Full Text] [PDF]

				K. Scotlandi, N. Baldini, V. Cerisano, M. C. Manara, S. Benini, M. Serra, P.-L. Lollini, P. Nanni, G. Nicoletti, G. Bernard, et al. CD99 Engagement: An Effective Therapeutic Strategy for Ewing Tumors Cancer Res., September 1, 2000; 60(18): 5134 - 5142. [Abstract] [Full Text]

				E. Mantadakis, L. Herrera, P. J. Leavey, R. O. Bash, N. J. Winick, and B. A. Kamen Fractionated Cyclophosphamide and Etoposide for Children With Advanced or Refractory Solid Tumors: A Phase II Window Study J. Clin. Oncol., July 1, 2000; 18(13): 2576 - 2581. [Abstract] [Full Text] [PDF]

				F. Cabanillas, S. Horning, M. Kaminski, and R. Champlin Managing Indolent Lymphomas in Relapse: Working Our Way Through a Plethora of Options Hematology, January 1, 2000; 2000(1): 166 - 179. [Abstract] [Full Text] [PDF]